Experience with hydroxyurea as a radiosensitizer in carcinoma of the cervix.
Since 1968, hydroxyurea has been used as a radiosensitizer in combination modality treatments for carcinoma of the cervix. The drug has shown an advantage over placebo in several randomized trials. Although hydroxyurea is given orally on an outpatient basis, it has not gained widespread acceptance. Previous reports are reviewed and possible future uses are discussed.
Stehman
F B
FB
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis.
D000818:Animals; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
D011838:Radiation-Sensitizing Agents; D006918:Hydroxyurea